PET radioligands reveal the basis of dementia in Parkinson's disease and dementia with lewy bodies

Neurodegenerative Diseases

Volumn 16, Issue 1-2, 2016, Pages 118-124

  Gomperts, Stephen N ^a   Marquie, Marta ^a   Locascio, Joseph J ^a   Bayer, Stephen ^a   Johnson, Keith A ^a   Growdon, John H ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Amyloid; Cognitive impairment; Dementia; Dementia with Lewy bodies; Dopamine transporter; Dopaminergic neurons; Neuroimaging; Parkinson's disease; Positron emission tomography; Tau protein

Indexed keywords

ALTROPANE C 11; PITTSBURGH COMPOUND B; RADIOPHARMACEUTICAL AGENT; T807 F 18; UNCLASSIFIED DRUG; 2-(4'-(METHYLAMINO)PHENYL)-6-HYDROXYBENZOTHIAZOLE; 7-(6-FLUOROPYRIDIN-3-YL)-5H-PYRIDO(4,3-B)INDOLE; ANILINE DERIVATIVE; CARBOLINE DERIVATIVE; COCAINE; N-IODOALLYL-2-CARBOMETHOXY-3-(4-FLUOROPHENYL)TROPANE; THIAZOLE DERIVATIVE;

ALZHEIMER DISEASE; COGNITION; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOBASAL DEGENERATION; CROSS-SECTIONAL STUDY; DEMENTIA; DIFFUSE LEWY BODY DISEASE; FUNCTIONAL DISEASE; GLOBUS PALLIDUS; HUMAN; MAJOR CLINICAL STUDY; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUTAMEN; ANALOGS AND DERIVATIVES; BRAIN; COGNITIVE DEFECT; COMPLICATION; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; PATHOLOGY; SCINTISCANNING; SURVIVAL ANALYSIS;

ALZHEIMER DISEASE; ANILINE COMPOUNDS; BRAIN; CARBOLINES; COCAINE; COGNITIVE DYSFUNCTION; CROSS-SECTIONAL STUDIES; DIAGNOSIS, DIFFERENTIAL; LEWY BODY DISEASE; MAGNETIC RESONANCE IMAGING; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PROSPECTIVE STUDIES; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS; SURVIVAL ANALYSIS; THIAZOLES;

EID: 84958035126     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000441421     Document Type: Conference Paper

References (23)

1. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, et al: Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65: 1863-1872.
2. Lippa CF, Duda JE, Grossman M, Hurtig HI, Aarsland D, Boeve BF, Brooks DJ, Dickson DW, Dubois B, Emre M, Fahn S, Farmer JM, Galasko D, Galvin JE, Goetz CG, Growdon JH, Gwinn-Hardy KA, Hardy J, Heutink P, Iwatsubo T, Kosaka K, Lee VM, Leverenz JB, Masliah E, McKeith IG, Nussbaum RL, Olanow CW, Ravina BM, Singleton AB, Tanner CM, Trojanowski JQ, Wszolek ZK; DLB/ PDD Working Group: DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 2007; 68: 812-819.
3. Huang Y, Halliday G: Can we clinically diagnose dementia with Lewy bodies yet? Transl Neurodegener 2013; 2: 4.
4. Politis M: Neuroimaging in Parkinson disease: from research setting to clinical practice. Nat Rev Neurol 2014; 10: 708-722.
5. Fischman AJ, Bonab AA, Babich JW, Livni E, Alpert NM, Meltzer PC, Madras BK: [(11)C, (127)I] Altropane: a highly selective ligand for PET imaging of dopamine transporter sites. Synapse 2001; 39: 332-342.
6. Marquie M, Locascio JJ, Rentz DM, Becker JA, Hedden T, Johnson KA, Growdon JH, Gomperts SN: Striatal and extrastriatal dopamine transporter levels relate to cognition in Lewy body diseases: an (11)C altropane positron emission tomography study. Alzheimers Res Ther 2014; 6: 52.
7. Harding AJ, Halliday GM: Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol 2001; 102: 355-363.
8. Howlett DR, Whitfield D, Johnson M, Attems J, O'Brien JT, Aarsland D, Lai MK, Lee JH, Chen C, Ballard C, Hortob?gyi T, Francis PT: Regional multiple pathology scores are associated with cognitive decline in Lewy body dementias. Brain Pathol 2015; 25: 401-408.
9. Gomperts SN: Imaging the role of amyloid in PD dementia and dementia with Lewy bodies. Curr Neurol Neurosci Rep 2014; 14: 472.
10. Andersson M, Zetterberg H, Minthon L, Blennow K, Londos E: The cognitive profile and CSF biomarkers in dementia with Lewy bodies and Parkinson's disease dementia. Int J Geriatr Psychiatry 2011; 26: 100-105.
11. Gomperts SN, Marquie-Sayagues M, Locascio JJ, Rentz D, Santarlasci AL, Johnson KA, Growdon JH: Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology 2013; 80: 85-91.
12. Siderowf A, Xie SX, Hurtig H, Weintraub D, Duda J, Chen-Plotkin A, Shaw LM, Van Deerlin V, Trojanowski JQ, Clark C: CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology 2010; 75: 1055-1061.
13. Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC: Tau imaging: early progress and future directions. Lancet Neurol 2015; 14: 114-124.
14. Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, Shankle WR, Elizarov A, Kolb HC: Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]- T807. J Alzheimers Dis 2013; 34: 457-468.
15. Hughes AJ, Daniel SE, Blankson S, Lees AJ: A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 1993; 50: 140-148.
16. Litvan I, Aarsland D, Adler CH, Goldman JG, Kulisevsky J, Mollenhauer B, Rodriguez-Oroz MC, Tröster AI, Weintraub D: MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord 2011; 26: 1814-1824.
17. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, Broe GA, Cummings J, Dickson DW, Gauthier S, Goldman J, Goetz C, Korczyn A, Lees A, Levy R, Litvan I, McKeith I, Olanow W, Poewe W, Quinn N, Sampaio C, Tolosa E, Dubois B: Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007; 22: 1689-1707.
18. Gomperts SN, Locascio JJ, Marquie-Sayagues M, Santarlasci AL, Rentz D, Maye J, Johnson KA, Growdon JH: Brain amyloid and cognition in Lewy body diseases. Mov Disord 2012; 27: 965-973.
19. Thie JA: Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med 2004; 45: 1431-1434.
20. Lewis DA, Melchitzky DS, Sesack SR, Whitehead RE, Auh S, Sampson A: Dopamine transporter immunoreactivity in monkey cerebral cortex: regional, laminar, and ultrastructural localization. J Comp Neurol 2001; 432: 119-136.
21. Becker JA, Hedden T, Carmasin J, Maye J, Rentz DM, Putcha D, Fischl B, Greve DN, Marshall GA, Salloway S, et al: Amyloid-beta associated cortical thinning in clinically normal elderly. Ann Neurol 2011; 69: 1032-1042.
22. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL: Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996; 16: 834-840.
23. Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, Meltzer CC, Schimmel K, Tsopelas ND, DeKosky ST, Price JC: Simplified quantification of Pittsburgh compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 2005; 46: 1959-1972.